Xconomy Insight is excited to offer two special webinars to our community this June. Sponsored by Eurofins, registration is free to all. Applying Cell-based In Vitro Assays to Improve In Vitro Hepatotoxicity Assessment Challenges Date: Wednesday, June 10, 2020 Time: 9:00am PDT / 12:00pm EDT Duration: 1 hour Register today In this webinar, we will … Continue reading “New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech”
Category: New York
Merck Outlines COVID-19 Ambitions With Buyout Deal, Collaborations
Merck exited the holiday weekend with some fireworks of its own, announcing three major programs on Tuesday all related to investments in finding ways to treat and prevent COVID-19. The Kenilworth, NJ-based pharma giant said it had inked an agreement to acquire Austrian vaccine developer Themis, which has a COVID-19 candidate in preclinical development; develop … Continue reading “Merck Outlines COVID-19 Ambitions With Buyout Deal, Collaborations”
Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq
COVID-19 has ravaged the economy, and it was expected to quash the IPO market, too. But the biotech sector is defying the pandemic with crossover financings and freshly minted public companies. On Friday, three firms added their names to the list of life science companies preparing to join the public markets. Gene therapy company Generation … Continue reading “Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq”
Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More
As the nation started to reopen this week following two months of closed businesses and stay-at-home orders, public health officials and economists cautioned that society won’t truly return to anything resembling a pre-pandemic normal without a COVID-19 vaccine. Moderna (NASDAQ: [[ticker:MRNA]]) moved one step closer to filling that need with the release of preliminary Phase … Continue reading “Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More”
AMAG Pharma Sells Off Women’s Health Product in Planned Divestment
AMAG Pharmaceuticals wants out of the women’s health business—and now it’s halfway there. On Thursday the Waltham, MA-based biotech said it had found a buyer for prasterone (Intrarosa), a steroid designed to treat pain during intercourse associated with menopause, one of two commercialized drugs it has been shopping around. The buyer of the AMAG Pharma … Continue reading “AMAG Pharma Sells Off Women’s Health Product in Planned Divestment”
Sunovion Drug Gets FDA Nod for Treating Parkinson’s “Off” Episodes
The FDA on Thursday approved a Sunovion Pharmaceuticals treatment for Parkinson’s disease, giving patients a new way to take an old drug. The Sunovion product, Kynmobi, is a formulation of apomorphine hydrochloride, a drug that treats “off” episodes experienced by Parkinson’s patients. These are times when the standard of care drug, levodopa, wears off and … Continue reading “Sunovion Drug Gets FDA Nod for Treating Parkinson’s “Off” Episodes”
Oligomerix Appoints Ex-Pfizer Exec Erhardt as Chief Medical Officer
Oligomerix this week added William Erhardt to its executive team as chief medical officer. Erhardt was most recently senior vice president, head of clinical development & operations at Pfizer (NYSE: [[ticker:PFE]]). New York-based Oligomerix, which is headquartered at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine, is developing small … Continue reading “Oligomerix Appoints Ex-Pfizer Exec Erhardt as Chief Medical Officer”
Merck Spinoff Organon Taps Ex-Allergan Execs Walsh, Stahler for C-Suite
Organon, a company spinning off from Merck (NYSE: [[ticker:MRK]]), is filling out its C-suite with the appointment of two new executives. Matthew Walsh is joining as chief financial officer; Rachel Stahler as chief information officer. Both come from Allergan, which was recently acquired by AbbVie (NYSE: [[ticker:ABBV]]). Walsh was Allergan’s executive vice president and CFO … Continue reading “Merck Spinoff Organon Taps Ex-Allergan Execs Walsh, Stahler for C-Suite”
Rallybio Lands $145M to Alter Course of FNAIT and More Rare Diseases
One of the risks to a newborn’s life comes from the mother’s immune system. It attacks the platelets of the fetus, depleting these blood-clotting cells and risking uncontrollable bleeding in the baby. Rallybio aims to develop the first FDA-approved treatment for this rare condition and the startup has raised $145 million to bring that drug, … Continue reading “Rallybio Lands $145M to Alter Course of FNAIT and More Rare Diseases”
ADC’s $233M IPO Brings It to NYSE With Cancer Drug Launch on Horizon
ADC Therapeutics is making its public markets debut, raising about $233 million six months after the cancer drug developer withdrew its initial IPO plans. Not only did Épalinges, Switzerland-based ADC go through with the stock offering this time around, it was also able to boost the deal’s size—not once, but three times. On Monday, the … Continue reading “ADC’s $233M IPO Brings It to NYSE With Cancer Drug Launch on Horizon”
Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More
This was a disappointing week for at least two major drug makers. French firm Genfit reported a trial failure in an intensely competitive indication, and New York-based Bristol Myers Squibb encountered a delay when the FDA declined to review its experimental multiple myeloma treatment. Genfit (NASDAQ: [[ticker:GNFT]]) was developing a treatment for nonalcoholic steatohepatitis, or … Continue reading “Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More”
From Overseas, Legend Biotech and Calliditas Therapeutics Eye the Nasdaq
Legend Biotech, a cancer cell therapy developer with roots in China, is preparing for a US stock exchange listing as its lead candidate keeps pace in the race for a multiple myeloma drug that addresses a new molecular target. The drug, known as JNJ-4528, is being developed in partnership with Johnson & Johnson (NYSE: [[ticker:JNJ]]) … Continue reading “From Overseas, Legend Biotech and Calliditas Therapeutics Eye the Nasdaq”
Biotech “Mapmaker” Immunai Launches With $20M to Chart the Immune System
It may seem like an unlikely link but the body’s response to arthritis may hold answers for better cancer drugs, says Luis Voloch, chief technology officer of startup Immunai. Immune cells respond to both conditions, but in different ways. Insights into the response for one disease could inform the treatment of the other, he says. … Continue reading “Biotech “Mapmaker” Immunai Launches With $20M to Chart the Immune System”
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Pipeline
Two preclinical programs developed by Canadian biotech Northern Biologics have been acquired by privately held German company Boehringer Ingelheim, which is looking to bolster its cancer immunology portfolio. The assets acquired from Northern Biologics in the deal, announced Thursday, are designed to target two aspects of what’s known as the tumor microenvironment: stroma, or connective … Continue reading “Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Pipeline”
BCMA Delay: FDA Refuses Review of Bristol Drug, Asks for More Info
Bristol Myers Squibb’s bid to win FDA approval for its multiple myeloma cell therapy has hit a detour. The FDA declined to review the experimental treatment and has instead asked the company to provide more information. Bristol (NYSE: [[ticker:BMY]]) announced Wednesday that it received a “refusal to file” letter for the experimental therapy, idecabtagene vicleucel … Continue reading “BCMA Delay: FDA Refuses Review of Bristol Drug, Asks for More Info”
Genfit Contender in Heated NASH Drug Race Fails in Phase 3 Study
Genfit, once considered among the frontrunners in the biotech race to commercialize a treatment for nonalcoholic steatohepatitis (NASH), has come up short. The French company said Monday that its investigational treatment, elafibranor, did not meet the main goal of a late-stage trial evaluating its ability to resolve the fatty liver disease without worsening related scarring. … Continue reading “Genfit Contender in Heated NASH Drug Race Fails in Phase 3 Study”
Eli Lilly Gets Edge in the “RET” Race With FDA Nod for Cancer Drug
[Updated, 5/11/2020, 10:03 a.m. See below.] Eli Lilly received accelerated FDA approval Friday for a drug that treats advanced cancers carrying a certain genetic signature. It’s the latest targeted cancer therapy to pass the regulatory bar and the first that addresses tumors characterized by aberrations in one particular gene. The gene in question, RET, produces … Continue reading “Eli Lilly Gets Edge in the “RET” Race With FDA Nod for Cancer Drug”
Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More
Alexion Pharmaceuticals CEO Ludwig Hantson has made no secret that he wants to diversify his company’s drug portfolio and he has shown willingness to open the corporate checkbook to accomplish that goal. Last October, Alexion (NASDAQ: [[ticker:ALXN]]) struck a $930 million deal to acquire Achillion Pharmaceuticals, a biotech whose lead drug complements the Boston company’s … Continue reading “Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More”
Ayala’s IPO Raises $55M to Test Two Former Bristol Myers Cancer Drugs
Ayala Pharmaceuticals has two clinical-stage cancer drugs licensed from Bristol Myers Squibb. Now it has $55 million to take those drugs further than the pharmaceutical giant did. On Thursday evening, Ayala priced its IPO, which consisted of 3.7 million shares sold for $15 each. That price was the midpoint of the targeted $14 to $16 … Continue reading “Ayala’s IPO Raises $55M to Test Two Former Bristol Myers Cancer Drugs”
PTC Therapeutics to Acquire Censa Pharma for Mid-Stage Rare Disease Drug
PTC Therapeutics has reached an agreement to acquire Censa Pharmaceuticals and its lead asset, an experimental metabolic disorder therapy that is now being prepared for a pivotal study. The deal, announced after the market close Wednesday, will bring South Plainfield, NJ-based PTC (NASDAQ: [[ticker:PTCT]]) another compound for its pipeline of rare disease drugs. Want more … Continue reading “PTC Therapeutics to Acquire Censa Pharma for Mid-Stage Rare Disease Drug”
Encouraging Signals for New Cancer Cell Therapy Strategies
Chimeric antigen receptor T-cell therapies have shown remarkable efficacy in leukemia and lymphoma patients who relapsed or were refractory to several prior treatments, but many challenges remain in the cancer cell therapy field. Strategies that may improve upon first-generation therapies were presented during the American Association for Cancer Research virtual meeting with encouraging early activity, … Continue reading “Encouraging Signals for New Cancer Cell Therapy Strategies”
Stemline Slated for Acquisition by Menarini in Deal Worth Up to $677M
Stemline Therapeutics, whose drug for a rare, aggressive type of acute leukemia was approved by the FDA about 18 months ago, has signed an acquisition deal with Italian biopharma Menarini Group. Stemline (NASDAQ: [[ticker:STML]]), a New York-based company, developed the first FDA-approved drug for blastic plasmacytoid dendritic cell neoplasm, or BPDCN. The drug, tagraxofusp (Elzonris) … Continue reading “Stemline Slated for Acquisition by Menarini in Deal Worth Up to $677M”
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
The genetic mutations that cause epilepsy don’t stop there. Praxis Precision Medicines CEO Marcio Souza says research also links these genes to other neurological conditions. The biotech startup is turning that research into new neuro drugs and it’s coming out of stealth to share details about its science and its pipeline, which already has two … Continue reading “Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs”
Pfizer Pays Valneva $130M for a Bite at a Lyme Disease Vaccine
If you’re looking for a Lyme disease vaccine, you can choose from among several—for your dog. A vaccine for humans hasn’t been available for years and few companies have tried to fill that void. Valneva has advanced its Lyme vaccine candidate to mid-stage clinical testing, and the company now has the help of drug giant … Continue reading “Pfizer Pays Valneva $130M for a Bite at a Lyme Disease Vaccine”
Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More
Remdesivir, the investigational Gilead Sciences antiviral drug, looks more likely than ever to become the first treatment authorized by the FDA to treat patients with COVID-19. National Institute of Allergy and Infectious Diseases (NIAID) head Anthony Fauci praised the drug after preliminary data released this week from a federally funded trial involving more than 1,000 … Continue reading “Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More”
ADC Therapeutics Resubmits IPO to Fuel Cancer Drug Filing, Launch Plans
Last fall, ADC Therapeutics (ADCT) concluded the time just wasn’t right for an IPO. Six months later, with its lead drug in a pivotal test and plans being drawn up for a regulatory submission and potential commercialization, the cancer drug developer has determined it needs cash now. ADCT refiled its IPO plans late Friday. The … Continue reading “ADC Therapeutics Resubmits IPO to Fuel Cancer Drug Filing, Launch Plans”
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
COVID-19’s spread has clamped down on a lot of economic activity, including the work of developing and testing new medicines. But the FDA isn’t showing signs of slowing down, at least when it comes to drugs filed for accelerated approval. The regulator signed off on three such drugs in the past week. These approvals are … Continue reading “Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More”
Affinivax Lands $120M to Take MAPS Tech Into New Vaccine Territory
Affinivax has a lead program with early clinical data showing the potential to best a pharmaceutical giant’s blockbuster vaccine. The startup now has $120 million in financing to see just how much further its technology can go. The Series B round of funding announced Thursday was led by Viking Global Investors. Cambridge, MA-based Affinivax develops … Continue reading “Affinivax Lands $120M to Take MAPS Tech Into New Vaccine Territory”
Immunomedics Triple Negative Breast Cancer Drug Wins Early FDA Nod
An Immunomedics therapy for an aggressive form of breast cancer won FDA approval on Wednesday. It’s the company’s first regulatory nod, and it covers a product expected to become a blockbuster seller. Morris Plains, NJ-based Immunomedics (NASDAQ: [[ticker:IMMU]]) developed the drug, sacituzumab govitecan (Trodelvy), as a treatment for treat triple negative breast cancer. This form … Continue reading “Immunomedics Triple Negative Breast Cancer Drug Wins Early FDA Nod”
Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19)
The start of a potentially big biomedical breakthrough is blooming within all of us. Drug research aiming to turn bacteria into microbiome therapies now spans programs aiming to address gut disorders, autism, cancer, and more. Given the number of late-stage and mid-stage studies expected to report data in 2020—assuming they stay on track amid the … Continue reading “Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19)”
Cara Therapeutics Itching Drug Scratches Off Goals of Phase 3 Test
A Cara Therapeutics drug developed to treat the severe itching experienced by patients receiving hemodialysis has met the main goal of a second late-stage study, setting up the experimental medicine for regulatory filings in the US and Europe. Cara (NASDAQ: [[ticker:CARA]]) is testing its injectable drug, difelikefalin (Korsuva), in patients who have moderate-to-severe chronic kidney … Continue reading “Cara Therapeutics Itching Drug Scratches Off Goals of Phase 3 Test”
New COVID-19 Special Reports Explore Clinical Research During the Pandemic
Two new special reports on Xconomy Insight provide an expert view on how companies can sustain clinical trials during the COVID-19 crisis. “Decentralized Clinical Trials: The Call for a New Paradigm” and “Sustaining Clinical Research During the Crisis” offer the latest trends and technologies companies can use to keep business running as smooth as possible. … Continue reading “New COVID-19 Special Reports Explore Clinical Research During the Pandemic”
PTC Therapeutics Promotes Matthew Klein, Eric Pauwels to C-Suite
Rare disease drug developer PTC Therapeutics (NASDAQ: [[ticker:PTCT]]) has promoted Matthew Klein to chief development officer. Klein joined the South Plainfield, NJ, biotech last year as global head of gene and mitochondrial therapies. He was previously CEO and chief medical officer of BioElectron Technology. PTC acquired some of BioElectron’s assets in 2019. In other moves, … Continue reading “PTC Therapeutics Promotes Matthew Klein, Eric Pauwels to C-Suite”
COVID-19 Vax Efforts Aim to Balance Speed, Efficacy in Race to Market
If Peter Marks had a magic wand to perfect the sophisticated process that takes a new vaccine from idea to reality, the US could have a way to prevent some people from COVID-19 infection in nine months to one year. In the real world, the journey to a vaccine OK’d under emergency guidelines is more … Continue reading “COVID-19 Vax Efforts Aim to Balance Speed, Efficacy in Race to Market”
Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More
The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn’t the only way for biotech companies to raise cash. Late last year Alnylam (NASDAQ: [[ticker:ALNY]]) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol. Alnylam had sold the drug’s development and commercialization … Continue reading “Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More”
UroGen Makes Chief Commercial & Chief Development Officer Promotions
UroGen Pharma (NASDAQ:[[ticker:URGN]]) has added two of its senior employees to the C-suite. The Princeton, NJ-based company, which Wednesday received FDA approval of its lead drug, promoted its senior vice president of commercial, Jeff Bova, to chief commercial officer, and its senior vice president of clinical development, Elyse Seltzer, to chief development officer. Bova and … Continue reading “UroGen Makes Chief Commercial & Chief Development Officer Promotions”
UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug
The FDA on Wednesday approved a drug developed by UroGen Pharma to treat low-grade upper tract urothelial cancer, which rarely spreads but often recurs and can cause kidney damage in some patients. Urothelial cancer is the most common type of bladder cancer. Upper tract urothelial cancer (UCTC), however, affects the lining of the urinary system, … Continue reading “UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug”
GSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year
[Updated, 3:13 p.m. See below.] Pharmaceutical giants GlaxoSmithKline and Sanofi are teaming up on COVID-19 research, aiming to combine their respective technologies in a new vaccine that could start clinical trials in coming months. The full details of the agreement, which was announced Tuesday, are still being finalized. But the companies say the vaccine would … Continue reading “GSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year”
Ex-Celgene Exec Brownstein Named Chief Medical Officer of Cellectis
Cellectis (NASDAQ: [[ticker:CLLS]]) has appointed Carrie Brownstein to serve as its chief medical officer. She worked most recently at Celgene as vice president of global clinical research and development and therapeutic area head for myeloid diseases. Celgene was acquired by Bristol Myers Squibb (NYSE: [[ticker:BMY]]) last year. Brownstein’s experience also includes positions at Regeneron Pharmaceuticals … Continue reading “Ex-Celgene Exec Brownstein Named Chief Medical Officer of Cellectis”
AstraZeneca Wins First FDA Drug Nod for NF1, a Rare Genetic Disorder
An AstraZeneca drug designed to block tumor growth is now approved as a treatment for neurofibromatosis type 1 (NF1), a rare inherited disorder that leads to tumors on nerves throughout the body. The FDA’s Friday decision for the drug, selumetinib (Koselugo), makes it the first approved treatment for NF1. It’s also the latest twist in … Continue reading “AstraZeneca Wins First FDA Drug Nod for NF1, a Rare Genetic Disorder”
Akero Heads to Top of Class in NASH; Genfit Says Pandemic Won’t Delay Data
Akero’s FGF21 analog yields 63 percent to 72 percent relative hepatic fat reduction in Phase 2a study; the company awaits biopsy data hoping to see a fibrotic benefit. Also, Genfit says COVID-19 pandemic should not significantly delay its Phase 3 NASH readout. FGF21 analogs comprise one of the more crowded classes in nonalcoholic steatohepatitis (NASH) … Continue reading “Akero Heads to Top of Class in NASH; Genfit Says Pandemic Won’t Delay Data”
Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More
The COVID-19 pandemic has stopped enrollment in many clinical trials and postponed the start of others but there is still life in the life sciences sector. The coronavirus research is expected. It’s the other activity that might come as a surprise. Two biotech companies have gone public in the past week; each upsized its offering and … Continue reading “Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More”
Pfizer, BioNTech Say mRNA COVID-19 Vaccine Trials May Start This Month
Multiple COVID-19 vaccine candidates that use a new technology called messenger RNA are now being readied for clinical trials that Pfizer and BioNTech plan to start in coming weeks. The partnership pairs the mRNA vaccine technology of BioNTech (NASDAQ: [[ticker:BNTX]]) with the vaccine and clinical trial experience of Pfizer (NYSE: [[ticker:PFE]]). The companies said Thursday … Continue reading “Pfizer, BioNTech Say mRNA COVID-19 Vaccine Trials May Start This Month”
Investors Bet on Next-Gen Telehealth as COVID-19 Fuels Adoption
Talking to a healthcare provider from the safety of one’s own home make more sense than ever today. Tyto Care offers a way to do so, plus a device that allows consumers to perform exams and transmit video, images, and sounds to their provider. This week the telehealth company doubled its outside investment to fuel … Continue reading “Investors Bet on Next-Gen Telehealth as COVID-19 Fuels Adoption”
Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics
Some diseases have proven difficult to address using conventional tools of drug discovery that target disease-causing proteins. Roche is placing a $190 million bet on Arrakis Therapeutics, a startup whose technology aims for RNA—carriers of the genetic instructions that make these proteins in the first place. The cash, an upfront payment to Waltham, MA-based Arrakis, … Continue reading “Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics”
Immunomedics Taps Ipsen’s Harout Semerjian as President and CEO
Immunomedics (NASDAQ: [[ticker:IMMU]]) has appointed Harout Semerjian to serve as its president and CEO. Semerjian is joining the Morris Plains, NJ-based cancer drug developer from Ipsen, where he is executive vice president and chief commercial officer. His experience also includes positions at Novartis (NYSE: [[ticker:NVS]]). Semerjian will start at Immunomedics on April 16. An FDA … Continue reading “Immunomedics Taps Ipsen’s Harout Semerjian as President and CEO”
Menlo’s Itching Drug Racks Up Two More Trial Failures, Program Ends
An itching drug that was a key part of the merger of Menlo Therapeutics and Foamix Pharmaceuticals has failed two late-stage studies, leading to a halt on further development of the compound. The Menlo (NASDAQ: [[ticker:MNLO]]) drug, serlopitant, was being tested in two Phase 3 clinical trials as a treatment for the itching associated with … Continue reading “Menlo’s Itching Drug Racks Up Two More Trial Failures, Program Ends”
Xconomy Releases Coronavirus Special Report on Containing the Pandemic Through Innovation & Investment
Based on the latest news and analysis, as well as conversations from industry experts during the Combatting Coronavirus live panel at BIO-Europe Spring®, Xconomy’s free special report delivers the latest COVID-19 news from the frontlines as top biotech and investment players offer their best plans and current progress in stemming and ultimately defeating the current … Continue reading “Xconomy Releases Coronavirus Special Report on Containing the Pandemic Through Innovation & Investment”
Zentalis Upsizes IPO, Raising $165M for Cancer Drug Clinical Trials
The global economic crash means the window for initial public stock offerings is all but closed but that didn’t stop Zentalis Phamaceuticals from pushing through. The clinical-stage drug developer priced its IPO late Thursday, raising $165.2 million in its stock market debut. Zentalis was able to sell more shares than it expected, and at a … Continue reading “Zentalis Upsizes IPO, Raising $165M for Cancer Drug Clinical Trials”
Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More
The coronavirus pandemic has shaken the global economy, but three life sciences venture capital firms this week announced new funds totaling nearly $3 billion. ARCH Venture Partners led the pack, adding two funds totaling $1.46 billion to its war chest. Flagship Pioneering bagged $1.1 billion, and venBio Partners reeled in $394 million. Flagship CEO Noubar … Continue reading “Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More”